IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
annual meeting of stockholders (the Annual Meeting). The final
results for each of the proposals submitted to a vote of the
Companys stockholders at the Annual Meeting are set forth below.
The proposals set forth below are described in detail in the
Company’s definitive proxy statement filed with the Securities
and Exchange Commission on April 26, 2017.
nominees as Class III directors to serve on the Board until the
2020 annual meeting of stockholders, or until their successors
are duly elected and qualified, by the votes set forth in the
table below: >
|
Nominee
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
Susan Kelley, M.D.
|
12,538,403
|
4,992,753
|
6,373,146
|
|
Carlos Paya, M.D., Ph.D.
|
12,555,319
|
4,975,837
|
6,373,146
|
|
William Ringo
|
10,748,760
|
6,782,396
|
6,373,146
|
Ernst Young LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2017 by
the votes set forth in the table below:
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Votes
|
|
23,881,208
|
23,094
|
About IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).
